Know-how of Target Discovery (with Innovative Target Discovery Platform for Metabolic Diseases, iClue-TDMD)
[Speaker] 최철수 / 가천의대
Comparing Platforms: siRNA, ASO, Ab, and Compound for the Treatment of Dyslipidemia
[Speaker] 박정숙 / 충남대
Which Target would Survive? Metabolism, Inflammation, or Aging?
[Speaker] 조경아 / 전남의대
Discussion